vs
Side-by-side financial comparison of Nano Dimension Ltd. (NNDM) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Twist Bioscience Corp is the larger business by last-quarter revenue ($103.7M vs $57.8M, roughly 1.8× Nano Dimension Ltd.). Twist Bioscience Corp runs the higher net margin — -29.4% vs -171.1%, a 141.6% gap on every dollar of revenue. Nano Dimension Ltd. produced more free cash flow last quarter ($-21.1M vs $-34.8M).
Nano Dimension Ltd. is a leading provider of additively manufactured electronics solutions and 3D printing technologies. It designs high-precision 3D printers, related materials, and software for producing printed circuit boards, microelectronics components, and multi-layer electronic devices, serving aerospace, defense, medical, automotive, and industrial electronics segments across global markets.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
NNDM vs TWST — Head-to-Head
Income Statement — Q4 FY2024 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $57.8M | $103.7M |
| Net Profit | $-98.8M | $-30.5M |
| Gross Margin | 43.1% | 52.0% |
| Operating Margin | -155.1% | -31.7% |
| Net Margin | -171.1% | -29.4% |
| Revenue YoY | — | 16.9% |
| Net Profit YoY | — | 3.4% |
| EPS (diluted) | $-0.45 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $103.7M | ||
| Q4 24 | $57.8M | — | ||
| Q2 24 | $28.4M | — | ||
| Q2 23 | $29.7M | — |
| Q4 25 | — | $-30.5M | ||
| Q4 24 | $-98.8M | — | ||
| Q2 24 | $-79.2M | — | ||
| Q2 23 | $12.6M | — |
| Q4 25 | — | 52.0% | ||
| Q4 24 | 43.1% | — | ||
| Q2 24 | 45.8% | — | ||
| Q2 23 | 44.0% | — |
| Q4 25 | — | -31.7% | ||
| Q4 24 | -155.1% | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | -29.4% | ||
| Q4 24 | -171.1% | — | ||
| Q2 24 | -279.4% | — | ||
| Q2 23 | 42.3% | — |
| Q4 25 | — | $-0.50 | ||
| Q4 24 | $-0.45 | — | ||
| Q2 24 | $-0.35 | — | ||
| Q2 23 | $0.05 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $317.2M | $197.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $860.0M | $456.1M |
| Total Assets | $902.5M | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $197.9M | ||
| Q4 24 | $317.2M | — | ||
| Q2 24 | $231.8M | — | ||
| Q2 23 | $454.6M | — |
| Q4 25 | — | $456.1M | ||
| Q4 24 | $860.0M | — | ||
| Q2 24 | $870.3M | — | ||
| Q2 23 | $1.1B | — |
| Q4 25 | — | $638.1M | ||
| Q4 24 | $902.5M | — | ||
| Q2 24 | $911.0M | — | ||
| Q2 23 | $1.2B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.9M | $-24.8M |
| Free Cash FlowOCF − Capex | $-21.1M | $-34.8M |
| FCF MarginFCF / Revenue | -36.5% | -33.5% |
| Capex IntensityCapex / Revenue | 3.8% | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-24.8M | ||
| Q4 24 | $-18.9M | — | ||
| Q2 24 | $-30.7M | — | ||
| Q2 23 | $-56.1M | — |
| Q4 25 | — | $-34.8M | ||
| Q4 24 | $-21.1M | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | -33.5% | ||
| Q4 24 | -36.5% | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | 9.6% | ||
| Q4 24 | 3.8% | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | -4.47× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NNDM
Segment breakdown not available.
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
